Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole

摘要

A method for treatment of gastric acid related diseases by inhibition of gastric acid secretion comprising administering to a mammal in need of treatment a therapeutically effective amount of the (- )- enantiomer of 5- methoxy-2-[[(4-methoxy-3,5-dimethyl-2- pyridinyl)methyl] sulfinyl]-1H- benzimidazole or a pharmaceutically acceptable salt thereof, so as to effect decreased interindividual variation in plasma levels upon administration. The use of the (-)- enantiomer of omeprazole to receive increased average plasma levels (AUC) upon administration of the same doses of the (-)-enantiomer of omeprazole compared to those of racemic omeprazole is also claimed, as well as an improved antisecretory effect and a better clinical effect.